{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:57:17Z","timestamp":1788368237041,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The development of suitable safe adjuvants to enhance appropriate antigen-driven immune responses remains a challenge. Here we describe the adjuvant properties of a small molecule activator of the integrins \u03b1L\u03b22 and \u03b14\u03b21, named 7HP349, which can be safely delivered systemically independent of antigen. 7HP349 directly activates integrin cell adhesion receptors crucial for the generation of an immune response. When delivered systemically in a model of Chagas disease following immunization with a DNA subunit vaccine encoding candidate<jats:italic>T. cruzi<\/jats:italic>antigens, TcG2 and TcG4, 7HP349 enhanced the vaccine efficacy in both prophylactic and therapeutic settings. In a prophylactic setting, mice immunized with 7HP349 adjuvanted vaccine exhibited significantly improved control of acute parasite burden in cardiac and skeletal muscle as compared to vaccination alone. When administered with vaccine therapeutically, parasite burden was again decreased, with the greatest adjuvant effect of 7HP349 being noted in skeletal muscle. In both settings, adjuvantation with 7HP349 was effective in decreasing pathological inflammatory infiltrate, improving the integrity of tissue, and controlling tissue fibrosis in the heart and skeletal muscle of acutely and chronically infected Chagas mice. The positive effects correlated with increased splenic frequencies of CD8<jats:sup>+<\/jats:sup>T effector cells and an increase in the production of IFN-\u03b3 and cytolytic molecules (perforin and granzyme) by the CD4<jats:sup>+<\/jats:sup>and CD8<jats:sup>+<\/jats:sup>effector and central memory subsets in response to challenge infection. This demonstrates that 7HP349 can serve as a systemically administered adjuvant to enhance T cell-mediated immune responses to vaccines. This approach could be applied to numerous vaccines with no reformulation of existing stockpiles.<\/jats:p>","DOI":"10.1038\/s41541-021-00378-5","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T10:02:46Z","timestamp":1631095366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Nandadeva","family":"Lokugamage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran H.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Biediger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert V.","family":"Market","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayadeth","family":"Khounlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin D.","family":"Warier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-An","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey K.","family":"Actor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren G.","family":"Woodside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upendra","family":"Marathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2990-6124","authenticated-orcid":false,"given":"Peter","family":"Vanderslice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-2369","authenticated-orcid":false,"given":"Nisha Jain","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"378_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.coi.2010.04.004","volume":"22","author":"ML Mbow","year":"2010","unstructured":"Mbow, M. L., De Gregorio, E., Valiante, N. M. & Rappuoli, R. New adjuvants for human vaccines. Curr. Opin. Immunol. 22, 411\u2013416 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"378_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1099\/jmm.0.039180-0","volume":"61","author":"P Oyston","year":"2012","unstructured":"Oyston, P. & Robinson, K. The current challenges for vaccine development. J. Med Microbiol. 61, 889\u2013894 (2012).","journal-title":"J. Med Microbiol."},{"key":"378_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1586\/erv.11.30","volume":"10","author":"N Petrovsky","year":"2011","unstructured":"Petrovsky, N. & Cooper, P. D. Carbohydrate-based immune adjuvants. Expert Rev. Vaccines 10, 523\u2013537 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"378_CR4","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1016\/S0264-410X(01)00193-1","volume":"19","author":"P Moingeon","year":"2001","unstructured":"Moingeon, P., Haensler, J. & Lindberg, A. Towards the rational design of Th1 adjuvants. Vaccine 19, 4363\u20134372 (2001).","journal-title":"Vaccine"},{"key":"378_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/346425a0","volume":"346","author":"TA Springer","year":"1990","unstructured":"Springer, T. A. Adhesion receptors of the immune system. Nature 346, 425\u2013434 (1990).","journal-title":"Nature"},{"key":"378_CR6","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.4049\/jimmunol.157.5.1965","volume":"157","author":"T Udagawa","year":"1996","unstructured":"Udagawa, T., Woodside, D. G. & McIntyre, B. W. Alpha 4 beta 1 (CD49d\/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation. J. Immunol. 157, 1965\u20131972 (1996).","journal-title":"J. Immunol."},{"key":"378_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1600-065X.1990.tb00563.x","volume":"114","author":"Y Shimizu","year":"1990","unstructured":"Shimizu, Y., van Seventer, G. A., Horgan, K. J. & Shaw, S. Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation. Immunol. Rev. 114, 109\u2013143 (1990).","journal-title":"Immunol. Rev."},{"key":"378_CR8","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.4049\/jimmunol.144.12.4579","volume":"144","author":"GA Van Seventer","year":"1990","unstructured":"Van Seventer, G. A., Shimizu, Y., Horgan, K. J. & Shaw, S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J. Immunol. 144, 4579\u20134586 (1990).","journal-title":"J. Immunol."},{"key":"378_CR9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.4049\/jimmunol.1700495","volume":"199","author":"NK Verma","year":"2017","unstructured":"Verma, N. K. & Kelleher, D. Not just an adhesion molecule: LFA-1 contact tunes the T lymphocyte program. J. Immunol. 199, 1213\u20131221 (2017).","journal-title":"J. Immunol."},{"key":"378_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.immuni.2007.12.016","volume":"28","author":"A Scholer","year":"2008","unstructured":"Scholer, A., Hugues, S., Boissonnas, A., Fetler, L. & Amigorena, S. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity 28, 258\u2013270 (2008).","journal-title":"Immunity"},{"key":"378_CR11","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1056\/NEJMoa030002","volume":"349","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl, M., Tyring, S. K., Hamilton, T. K., Toth, D. & Glazer, S. et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349, 2004\u20132013 (2003).","journal-title":"N. Engl. J. Med."},{"key":"378_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/OPTH.S117188","volume":"11","author":"MR Godin","year":"2017","unstructured":"Godin, M. R. & Gupta, P. K. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy. Clin. Ophthalmol. 11, 951\u2013957 (2017).","journal-title":"Clin. Ophthalmol."},{"key":"378_CR13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman, C. H., O\u2019Connor, P. W., Havrdova, E., Hutchinson, M. & Kappos, L. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899\u2013910 (2006).","journal-title":"N. Engl. J. Med."},{"key":"378_CR14","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G. & Hanauer, S. B. et al. Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N. Engl. J. Med. 353, 1912\u20131925 (2005).","journal-title":"N. Engl. J. Med."},{"key":"378_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nrrheum.2009.142","volume":"5","author":"ES Molloy","year":"2009","unstructured":"Molloy, E. S. & Calabrese, L. H. Therapy: targeted but not trouble-free: efalizumab and PML. Nat. Rev. Rheumatol. 5, 418\u2013419 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"378_CR16","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.4049\/jimmunol.1601358","volume":"198","author":"A Shirani","year":"2017","unstructured":"Shirani, A. & Stuve, O. Natalizumab for multiple sclerosis: a case in point for the impact of translational neuroimmunology. J. Immunol. 198, 1381\u20131386 (2017).","journal-title":"J. Immunol."},{"key":"378_CR17","doi-asserted-by":"publisher","first-page":"19414","DOI":"10.1074\/jbc.M113.479634","volume":"288","author":"P Vanderslice","year":"2013","unstructured":"Vanderslice, P., Biediger, R. J., Woodside, D. G., Brown, W. S. & Khounlo, S. et al. Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion. J. Biol. Chem. 288, 19414\u201319428 (2013).","journal-title":"J. Biol. Chem."},{"key":"378_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40588-018-0081-2","volume":"5","author":"M Lopez","year":"2018","unstructured":"Lopez, M., Tanowitz, H. B. & Garg, N. J. Pathogenesis of chronic Chagas disease: macrophages, mitochondria, and oxidative stress. Curr. Clin. Microbiol. Rep. 5, 45\u201354 (2018).","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"378_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev-pathol-020117-043711","volume":"14","author":"KM Bonney","year":"2020","unstructured":"Bonney, K. M., Luthringer, D. J., Kim, S. A., Garg, N. J. & Engman, D. M. Pathology and pathogenesis of Chagas heart disease. Annu. Rev. Pathol. 14, 421\u2013447 (2020).","journal-title":"Annu. Rev. Pathol."},{"key":"378_CR20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1089\/ars.2016.6831","volume":"27","author":"JJ Wen","year":"2017","unstructured":"Wen, J. J., Porter, C. & Garg, N. J. Inhibition of NFE2L2-antioxidant response element pathway by mitochondrial reactive oxygen species contributes to development of cardiomyopathy and left ventricular dysfunction in Chagas disease. Antioxid. Redox Signal. 27, 550\u2013566 (2017).","journal-title":"Antioxid. Redox Signal."},{"key":"378_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4049\/jimmunol.175.2.633","volume":"175","author":"JJ Donnelly","year":"2005","unstructured":"Donnelly, J. J., Wahren, B. & Liu, M. A. DNA vaccines: progress and challenges. J. Immunol. 175, 633\u2013639 (2005).","journal-title":"J. Immunol."},{"key":"378_CR22","doi-asserted-by":"publisher","first-page":"90520","DOI":"10.1155\/2007\/90520","volume":"2007","author":"E Dumonteil","year":"2007","unstructured":"Dumonteil, E. DNA vaccines against protozoan parasites: advances and challenges. J. Biomed. Biotechnol. 2007, 90520 (2007).","journal-title":"J. Biomed. Biotechnol."},{"key":"378_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/B978-0-12-385863-4.00006-X","volume":"75","author":"JC V\u00e1zquez-Chagoy\u00e1n","year":"2011","unstructured":"V\u00e1zquez-Chagoy\u00e1n, J. C., Gupta, S. & Garg, N. J. Vaccine development against Trypanosoma cruzi and Chagas disease. Adv. Parasitol. 75, 121\u2013146 (2011).","journal-title":"Adv. Parasitol."},{"key":"378_CR24","doi-asserted-by":"publisher","first-page":"243786","DOI":"10.1155\/2014\/243786","volume":"2014","author":"F Dos Santos Virgilio","year":"2014","unstructured":"Dos Santos Virgilio, F., Pontes, C., Dominguez, M. R., Ersching, J. & Rodrigues, M. M. et al. CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development? Mediators Inflamm. 2014, 243786 (2014).","journal-title":"Mediators Inflamm."},{"key":"378_CR25","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1128\/IAI.72.11.6245-6254.2004","volume":"72","author":"V Bhatia","year":"2004","unstructured":"Bhatia, V., Sinha, M., Luxon, B. & Garg, N. J. Utility of Trypanosoma cruzi sequence database for the identification of potential vaccine candidates: In silico and in vitro screening. Infect. Immun. 72, 6245\u20136254 (2004).","journal-title":"Infect. Immun."},{"key":"378_CR26","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1128\/CVI.00144-08","volume":"15","author":"V Bhatia","year":"2008","unstructured":"Bhatia, V. & Garg, N. J. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin. Vaccin. Immunol. 15, 1158\u20131164 (2008).","journal-title":"Clin. Vaccin. Immunol."},{"key":"378_CR27","doi-asserted-by":"publisher","first-page":"e1050","DOI":"10.1371\/journal.pntd.0001050","volume":"5","author":"JE Aparicio-Burgos","year":"2011","unstructured":"Aparicio-Burgos, J. E., Ochoa-Garcia, L., Zepeda-Escobar, J. A., Gupta, S. & Dhiman, M. et al. Testing the efficacy of a multi-component DNA-prime\/DNA-boost vaccine against Trypanosoma cruzi infection in dogs. PLoS Negl. Trop. Dis. 5, e1050 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"378_CR28","first-page":"e2018","volume":"7","author":"S Gupta","year":"2013","unstructured":"Gupta, S., Wan, X.-X., Zago, M. P., Martinez, V. C. S. & Silva, T. S. et al. Antigenicity and diagnostic potential of vaccine candidates in human Chagas disease. PLoS NTD 7, e2018 (2013).","journal-title":"PLoS NTD"},{"key":"378_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1586\/14760584.4.6.867","volume":"4","author":"V Bhatia","year":"2005","unstructured":"Bhatia, V. & Garg, N. J. Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev. Vaccines 4, 867\u2013880 (2005).","journal-title":"Expert Rev. Vaccines"},{"key":"378_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/ijms19020485","volume":"19","author":"A Bertoni","year":"2018","unstructured":"Bertoni, A., Alabiso, O., Galetto, A. S. & Baldanzi, G. Integrins in T cell physiology. Int. J. Mol. Sci. 19, 485 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"378_CR31","doi-asserted-by":"publisher","first-page":"e0003625","DOI":"10.1371\/journal.pntd.0003625","volume":"9","author":"JE Aparicio-Burgos","year":"2015","unstructured":"Aparicio-Burgos, J. E., Zepeda-Escobar, J. A., de Oca-Jimenez, R. M., Estrada-Franco, J. G. & Barbabosa-Pliego, A. et al. Immune protection against Trypanosoma cruzi induced by TcVac4 in a canine model. PLoS Negl. Trop. Dis. 9, e0003625 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"378_CR32","doi-asserted-by":"publisher","first-page":"e59434","DOI":"10.1371\/journal.pone.0059434","volume":"8","author":"S Gupta","year":"2013","unstructured":"Gupta, S. & Garg, N. J. TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice. PLoS ONE 8, e59434 (2013).","journal-title":"PLoS ONE"},{"key":"378_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0020-7519(02)00283-7","volume":"33","author":"R Perez-Fuentes","year":"2003","unstructured":"Perez-Fuentes, R., Guegan, J. F., Barnabe, C., Lopez-Colombo, A. & Salgado-Rosas, H. et al. Severity of chronic Chagas disease is associated with cytokine\/antioxidant imbalance in chronically infected individuals. Int. J. Parasitol. 33, 293\u2013299 (2003).","journal-title":"Int. J. Parasitol."},{"key":"378_CR34","doi-asserted-by":"publisher","first-page":"7960","DOI":"10.1128\/IAI.73.12.7960-7966.2005","volume":"73","author":"JA Gomes","year":"2005","unstructured":"Gomes, J. A., Bahia-Oliveira, L. M., Rocha, M. O., Busek, S. C. & Teixeira, M. M. et al. Type 1 chemokine receptor expression in Chagas\u2019 disease correlates with morbidity in cardiac patients. Infect. Immun. 73, 7960\u20137966 (2005).","journal-title":"Infect. Immun."},{"key":"378_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.autrev.2010.09.019","volume":"10","author":"E Cunha-Neto","year":"2011","unstructured":"Cunha-Neto, E., Teixeira, P. C., Fonseca, S. G., Bilate, A. M. & Kalil, J. Myocardial gene and protein expression profiles after autoimmune injury in Chagas\u2019 disease cardiomyopathy. Autoimmun. Rev. 10, 163\u2013165 (2011).","journal-title":"Autoimmun. Rev."},{"key":"378_CR36","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/pim.12183","volume":"37","author":"RH Vasconcelos","year":"2015","unstructured":"Vasconcelos, R. H., Azevedo Ede, A., Diniz, G. T., Cavalcanti Mda, G. & de Oliveira, W. Jr. et al. Interleukin-10 and tumour necrosis factor-alpha serum levels in chronic Chagas disease patients. Parasite Immunol. 37, 376\u2013379 (2015).","journal-title":"Parasite Immunol."},{"key":"378_CR37","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3389\/fimmu.2019.01456","volume":"10","author":"S Gupta","year":"2019","unstructured":"Gupta, S., Salgado-Jimenez, B., Lokugamage, N., Vazquez-Chagoyan, J. C. & Garg, N. J. TcG2\/TcG4 DNA vaccine induces Th1 immunity against acute Trypanosoma cruzi infection: adjuvant and antigenic effects of heterologous T. rangeli booster immunization. Front. Immunol. 10, 1456 (2019).","journal-title":"Front. Immunol."},{"key":"378_CR38","doi-asserted-by":"publisher","first-page":"e1004828","DOI":"10.1371\/journal.ppat.1004828","volume":"11","author":"S Gupta","year":"2015","unstructured":"Gupta, S. & Garg, N. J. A two-component DNA-prime\/protein-boost vaccination strategy for eliciting long-term, protective T cell immunity against Trypanosoma cruzi. PLoS Pathog. 11, e1004828 (2015).","journal-title":"PLoS Pathog."},{"key":"378_CR39","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1016\/j.vaccine.2007.01.114","volume":"25","author":"B Basso","year":"2007","unstructured":"Basso, B., Castro, I., Introini, V., Gil, P. & Truyens, C. et al. Vaccination with Trypanosoma rangeli reduces the infectiousness of dogs experimentally infected with Trypanosoma cruzi. Vaccine 25, 3855\u20133858 (2007).","journal-title":"Vaccine"},{"key":"378_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.vetimm.2013.10.011","volume":"157","author":"B Basso","year":"2014","unstructured":"Basso, B., Moretti, E. & Fretes, R. Vaccination with Trypanosoma rangeli induces resistance of guinea pigs to virulent Trypanosoma cruzi. Vet. Immunol. Immunopathol. 157, 119\u2013123 (2014).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"378_CR41","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/21645515.2016.1242540","volume":"13","author":"CA Seid","year":"2017","unstructured":"Seid, C. A., Jones, K. M., Pollet, J., Keegan, B. & Hudspeth, E. et al. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum. Vaccin Immunother. 13, 621\u2013633 (2017).","journal-title":"Hum. Vaccin Immunother."},{"key":"378_CR42","doi-asserted-by":"publisher","first-page":"e0007413","DOI":"10.1371\/journal.pntd.0007413","volume":"13","author":"MA Barry","year":"2019","unstructured":"Barry, M. A., Versteeg, L., Wang, Q., Pollet, J. & Zhan, B. et al. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl. Trop. Dis. 13, e0007413 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"378_CR43","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.1016\/j.vaccine.2020.10.006","volume":"38","author":"LD Caeiro","year":"2020","unstructured":"Caeiro, L. D., Masip, Y. E., Rizzi, M., Rodriguez, M. E. & Pueblas Castro, C. et al. The Trypanosoma cruzi TcTASV-C protein subfamily administrated with U-Omp19 promotes a protective response against a lethal challenge in mice. Vaccine 38, 7645\u20137653 (2020).","journal-title":"Vaccine"},{"key":"378_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0010-z","volume":"2","author":"A Sanchez Alberti","year":"2017","unstructured":"Sanchez Alberti, A., Bivona, A. E., Cerny, N., Schulze, K. & Weissmann, S. et al. Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection. NPJ Vaccines 2, 9 (2017).","journal-title":"NPJ Vaccines"},{"key":"378_CR45","doi-asserted-by":"crossref","unstructured":"Woodside, D. G. & Vanderslice, P. Inflammation and regulation by integrin cell adhesion antagonists. In Translational Inflammation (ed. Csencsits-Smith, J. K.) Chapter. 3, 43\u201368 (Elsevier, 2018).","DOI":"10.1016\/B978-0-12-813832-8.00003-0"},{"key":"378_CR46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4049\/jimmunol.1601999","volume":"199","author":"B Larkin","year":"2017","unstructured":"Larkin, B., Ilyukha, V., Sorokin, M., Buzdin, A. & Vannier, E. et al. Cutting edge: activation of sting in T cells induces type I IFN responses and cell death. J. Immunol. 199, 397\u2013402 (2017).","journal-title":"J. Immunol."},{"key":"378_CR47","doi-asserted-by":"publisher","first-page":"e12769","DOI":"10.1111\/pim.12769","volume":"42","author":"LE Villanueva-Lizama","year":"2020","unstructured":"Villanueva-Lizama, L. E., Cruz-Chan, J. V., Versteeg, L., Teh-Poot, C. F. & Hoffman, K. et al. TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac parasite burdens. Parasite Immunol. 42, e12769 (2020).","journal-title":"Parasite Immunol."},{"key":"378_CR48","unstructured":"Clinical trial: A phase 1 SAD and MAD study of the safety, tolerability and PK of 7HP349 in normal healthy subjects, Sponsor: 7 Hills Pharma, LLC, https:\/\/clinicaltrials.gov\/ct2\/results?recrs=&cond=&term=7HP349&cntry=&state=&city=&dist=."},{"key":"378_CR49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.cellimm.2011.04.010","volume":"269","author":"A Ciaramella","year":"2011","unstructured":"Ciaramella, A., Spalletta, G., Bizzoni, F., Salani, F. & Caltagirone, C. et al. Effect of age on surface molecules and cytokine expression in human dendritic cells. Cell Immunol. 269, 82\u201389 (2011).","journal-title":"Cell Immunol."},{"key":"378_CR50","unstructured":"Biediger, R. J. & Market, R. V. Agonists that enhanced binding of integrin-expressing cells to integrin receptors, US Patent 10071980, Texas Heart Institute, Issued Sept. 11, (2018)."},{"key":"378_CR51","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.bbrc.2010.08.114","volume":"400","author":"P Vanderslice","year":"2010","unstructured":"Vanderslice, P., Woodside, D. G., Caivano, A. R., Decker, E. R. & Munsch, C. L. et al. Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin alpha4beta1. Biochem. Biophys. Res Commun. 400, 619\u2013624 (2010).","journal-title":"Biochem. Biophys. Res Commun."},{"key":"378_CR52","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0925-4439(03)00060-7","volume":"1638","author":"NJ Garg","year":"2003","unstructured":"Garg, N. J., Popov, V. L. & Papaconstantinou, J. Profiling gene transcription reveals a deficiency of mitochondrial oxidative phosphorylation in Trypanosoma cruzi-infected murine hearts: implications in chagasic myocarditis development. Biochim. Biophys. Acta 1638, 106\u2013120 (2003).","journal-title":"Biochim. Biophys. Acta"},{"key":"378_CR53","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1042\/BJ20040356","volume":"381","author":"NJ Garg","year":"2004","unstructured":"Garg, N. J., Bhatia, V., Gerstner, A., deFord, J. & Papaconstantinou, J. Gene expression analysis in mitochondria from chagasic mice: Alterations in specific metabolic pathways. Biochem. J. 381, 743\u2013752 (2004).","journal-title":"Biochem. J."},{"key":"378_CR54","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbadis.2004.03.005","volume":"1689","author":"G Vyatkina","year":"2004","unstructured":"Vyatkina, G., Bhatia, V., Gerstner, A., Papaconstantinou, J. & Garg, N. J. Impaired mitochondrial respiratory chain and bioenergetics during chagasic cardiomyopathy development. Biochim. Biophys. Acta 1689, 162\u2013173 (2004).","journal-title":"Biochim. Biophys. Acta"},{"key":"378_CR55","doi-asserted-by":"publisher","first-page":"e797","DOI":"10.1371\/journal.pntd.0000797","volume":"4","author":"S Gupta","year":"2010","unstructured":"Gupta, S. & Garg, N. J. Prophylactic efficacy of TcVac2R against Trypanosoma cruzi in mice. PLoS Negl. Trop. Dis. 4, e797 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"378_CR56","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3389\/fimmu.2019.01194","volume":"10","author":"S Toghi Eshghi","year":"2019","unstructured":"Toghi Eshghi, S., Au-Yeung, A., Takahashi, C., Bolen, C. R. & Nyachienga, M. N. et al. Quantitative comparison of conventional and t-SNE-guided gating analyses. Front. Immunol. 10, 1194 (2019).","journal-title":"Front. Immunol."},{"key":"378_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000451055","volume":"9","author":"I Chowdhury","year":"2017","unstructured":"Chowdhury, I., Koo, S., Gupta, S., Liang, L. Y. & Bahar, B. et al. Gene expression profiling and functional characterization of macrophages in response to circulatory microparticles produced during Trypanosoma cruzi infection and Chagas disease. J. Innate Immun. 9, 203\u2013216 (2017).","journal-title":"J. Innate Immun."},{"key":"378_CR58","doi-asserted-by":"publisher","first-page":"e1007065","DOI":"10.1371\/journal.ppat.1007065","volume":"14","author":"JJ Wen","year":"2018","unstructured":"Wen, J. J., Yin, Y. W. & Garg, N. J. PARP1 depletion improves mitochondrial and heart function in Chagas disease: Effects on POLG dependent mtDNA maintenance. PLoS Pathog. 14, e1007065 (2018).","journal-title":"PLoS Pathog."},{"key":"378_CR59","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/path.2975","volume":"225","author":"M Dhiman","year":"2011","unstructured":"Dhiman, M. & Garg, N. J. NADPH oxidase inhibition ameliorates Trypanosoma cruzi-induced myocarditis during Chagas disease. J. Pathol. 225, 583\u2013596 (2011).","journal-title":"J. Pathol."},{"key":"378_CR60","doi-asserted-by":"publisher","first-page":"e000302","DOI":"10.1161\/JAHA.113.000302","volume":"2","author":"M Dhiman","year":"2013","unstructured":"Dhiman, M., Wan, X.-X., Popov, L. V., Vargas, G. & Garg, N. J. MnSODtg mice control myocardial inflammatory and oxidative stress and remodeling responses elicited in chronic Chagas disease. J. Am. Heart Assoc. 2, e000302 (2013).","journal-title":"J. Am. Heart Assoc."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00378-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00378-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00378-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T20:47:10Z","timestamp":1673210830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00378-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00378-5","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"12 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.J.G., I.H.C., N.L., S.K., N.D.W., and S.-A.H. declare that there are no competing interests. J.A.K., P.V., and D.G.W. are advisors to 7 Hills Pharma. U.M., P.V., D.G.W., R.J.B., and R.V.M. are investors, hold founder\u2019s shares in 7 Hills Pharma, and are inventors on issued patents related to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}